Genpharmasec Board of Directors

Get the latest insights into the leadership at Genpharmasec. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Sohan ChaturvediWhole Time Director & Chief Financial Officer
Rajesh SadhwaniNon Independent & Non Executive Director
Sneha SadhwaniNon Independent & Non Executive Director
Siddhesh ShendeNon Executive Independent Director
Mayur BhattNon Executive Independent Director
Sachin AphandkarNon Executive Independent Director
Hardik MakwanaCompany Secretary & Compliance Officer

Genpharmasec Share price

GENPHARMA

1.27

0.01 (0.79%)
Last updated on 24 Apr, 2026 | 15:29 IST
Today's High

1.32

Today's Low

1.24

52 Week Low

0.75

52 Week High

2.38

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Genpharmasec FAQs

The board at Genpharmasec consists of experienced professionals, including Sohan Chaturvedi, Rajesh Sadhwani, and others, overseeing the company’s strategic and corporate governance.

Directors at Genpharmasec are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Sohan Chaturvedi is the current chairman at Genpharmasec.

Executive directors at Genpharmasec are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Genpharmasec adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Genpharmasec, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost